XML 48 R35.htm IDEA: XBRL DOCUMENT
v3.26.1

Business Segment (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2026
Segment Reporting [Abstract] |
Summary of Segment Reporting Information | The table below is a summary of the segment net loss, including significant segment expenses (in millions):
|  |  | Three Months Ended March 31,
|  |  |  |  |  |  | 2026 |  | 2025
Total revenues |  |  |  |  |  |  | 17 |  |  | 28 |
Adjusted for expense (income): |  |  |  |  |  |  |  |  |
Late-stage development programs (1) |  |  |  |  |  |  | 60 |  |  | 55 |
Early-stage development and preclinical programs (2) |  |  |  |  |  |  | 18 |  |  | 42 |
Compensation and personnel costs |  |  |  |  |  |  | 70 |  |  | 66 |
Depreciation and amortization |  |  |  |  |  |  | 2 |  |  | 3 |
Interest income, net |  |  |  |  |  |  | (6) |  |  | (10) |
Other segment items (3) |  |  |  |  |  |  | 20 |  |  | 22 |
Partnership reimbursements |  |  |  |  |  |  | (19) |  |  | (38) |
Segment net loss and Consolidated net loss |  |  |  |  |  |  | $ | (128) |  |  | $ | (112) |
(1) R&D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once the related program enters into one or more Phase 3 clinical trials. (2) R&D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials. (3) Other segment items includes non-allocated program costs and other G&A costs.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration